Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06285214 · ClinicalTrials.gov registry record · Phase 1
Study of V117957 in Interstitial Cystitis/Bladder Pain Syndrome
A Phase 1 study, sponsored by Imbrium Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 47
- Enrollment target
NCT06285214 is a Phase 1 study that has completed, run by Imbrium Therapeutics. The registered enrollment target is 47 participants.
The verdict
NCT06285214, a Phase 1 study, has completed, sponsored by Imbrium Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 47 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety, tolerability and efficacy of V117957 in subjects with interstitial cystitis/bladder pain syndrome, compared to placebo.
Interventions
- DRUG Placebo
- DRUG V117957
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 47 participants |
| Start Date | 2022-05-26 |
| Est. Completion | 2025-01-28 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06285214
The ClinicalTrials.gov registry entry for NCT06285214 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 47 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Imbrium Therapeutics, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT06285214 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06285214 about?
NCT06285214 is a clinical study titled "Study of V117957 in Interstitial Cystitis/Bladder Pain Syndrome". The purpose of this study is to evaluate the safety, tolerability and efficacy of V117957 in subjects with interstitial cystitis/bladder pain syndrome, compared to placebo.
What is the current status of trial NCT06285214?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 47 participants. The study started on 2022-05-26. Estimated completion is 2025-01-28.
What interventions are being tested in trial NCT06285214?
The interventions under investigation include: Placebo (DRUG), V117957 (DRUG).
Who is sponsoring clinical trial NCT06285214?
This trial is sponsored by Imbrium Therapeutics, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.